Literature DB >> 17949754

Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling.

Maciej Jurynczyk1, Anna Jurewicz, Bartosz Bielecki, Cedric S Raine, Krzysztof Selmaj.   

Abstract

In multiple sclerosis (MS), myelin destroyed by the immune attack is not effectively repaired by oligodendrocytes (OLs) and MS foci eventually undergo glial scarring. Although oligodendrocyte precursor cells (OPCs) are normally recruited to the lesion areas, they fail to mature and remyelinate the damaged fibers. Activation of the Notch pathway has been shown to inhibit OPC differentiation and to hamper their ability to produce myelin during CNS development. We have recently shown that inhibition of gamma-secretase within the CNS of SJL/J mice with experimental autoimmune encephalomyelitis (EAE) blocks Notch pathway activation in OLs, promotes remyelination, reduces axonal damage and significantly enhances clinical recovery from the disease. Our results suggest that inhibiting the non-myelin permissive environment maintained by Notch pathways within the mature CNS offers a new strategy for treating autoimmune demyelination, including MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949754     DOI: 10.1016/j.jns.2007.09.007

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Notch signaling regulates mouse and human Th17 differentiation.

Authors:  Shilpa Keerthivasan; Reem Suleiman; Rebecca Lawlor; Justine Roderick; Tonya Bates; Lisa Minter; Juan Anguita; Ignacio Juncadella; Brian J Nickoloff; I Caroline Le Poole; Lucio Miele; Barbara A Osborne
Journal:  J Immunol       Date:  2011-06-17       Impact factor: 5.422

Review 2.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

Review 3.  The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges.

Authors:  Robert P Murphy; Keith J Murphy; Mark Pickering
Journal:  Bioengineered       Date:  2012-11-12       Impact factor: 3.269

4.  Notch signaling regulates T cell accumulation and function in the central nervous system during experimental autoimmune encephalomyelitis.

Authors:  Ashley R Sandy; Josh Stoolman; Kelli Malott; Prae Pongtornpipat; Benjamin M Segal; Ivan Maillard
Journal:  J Immunol       Date:  2013-07-03       Impact factor: 5.422

Review 5.  Not(ch) just development: Notch signalling in the adult brain.

Authors:  Jessica L Ables; Joshua J Breunig; Amelia J Eisch; Pasko Rakic
Journal:  Nat Rev Neurosci       Date:  2011-05       Impact factor: 34.870

Review 6.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 7.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Notch signaling activation is critical to the development of neuropathic pain.

Authors:  Keliang Xie; Feng Qiao; Yanyan Sun; Guolin Wang; Lichao Hou
Journal:  BMC Anesthesiol       Date:  2015-03-28       Impact factor: 2.217

10.  Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.

Authors:  Matthew Cummings; Anitha Christy Sigamani Arumanayagam; Picheng Zhao; Sunil Kannanganat; Olaf Stuve; Nitin J Karandikar; Todd N Eagar
Journal:  PLoS One       Date:  2018-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.